Key result
NN703 dose-dependently increases GH release in swine and dogs and weight gain in rats.
Population
Preclinical models: rat pituitary cells, BHK cells expressing human GHS-R 1A, swine, beagle dogs, and rats.
Comparison
NN703 administered in vitro, intravenously, and… vs Vehicle, GHRP-6, and MK677.
Design
Preclinical
Follow-up
14 days (for rat body weight study)
Authors
Loading...
NN703 merits human pharmacokinetic and safety studies; leaves open translation to GH deficiency or growth disorders.
NN703 is a novel, orally active, and specific GH secretagogue that effectively stimulates GH release and increases body weight gain in preclinical models.
Hansen et al. (1999) studied this question. NN703 vs. vehicle / basal levels was evaluated on GH release and body weight gain. NN703, a novel orally active GH secretagogue, dose-dependently increased GH release in swine and dogs and significantly increased body weight gain in rats over 14 days compared with vehicle.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: